advertisement
Abstract #8243 Published in IGR 4-3
A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension
Tsukamoto H; Mishima HK; Kitazawa Y; Araie M; Abe H; Negi A; Glaucoma Study GroupJournal of Glaucoma 2002; 11: 497-501
PURPOSE: To compare the efficacy and safety of latanoprost versus isopropyl unoprostone (unoprostone) in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). METHODS: An eight-week, multicenter, randomized, comparative study was performed in 48 Japanese patients with POAG or OH. Four patients (two in each group) withdrew from the study, but their data were included in the safety assessment, but not in the intraocular pressure (IOP) evaluation. The patients were randomly treated with latanoprost 0.005% once daily or unoprostone 0.12% twice daily for eight weeks. IOP was measured at baseline and at two, four, and eight weeks after treatment. In addition, ocular and systemic adverse events were recorded. RESULTS: The baseline IOPs were similar between the latanoprost (n = 25) and unoprostone (n = 19) groups (24.3 ± 2.4 versus 23.3 ± 2.1 mmHg, respectively, p = 0.18). The IOP reductions from baseline at two, four, and eight weeks after treatment were 5.8 ± 2.4, 6.6 ± 2.5, and 6.7 ± 2.0 mmHg in the latanoprost, and 3.8 ± 2.0, 3.5 ± 2.3, and 3.3 ± 3.0 mmHg in the unoprostone group, respectively. The IOP reduction in the latanoprost group at eight weeks was larger than that in the unoprostone group (p < 0.001, analysis of covariance). Five adverse events were observed in four (15%) of 27 patients in the latanoprost group, and five adverse events in four (20%) of 21 patients in the unoprostone group. There was no difference in the incidence of adverse events between groups (p = 0.71). CONCLUSION: Latanoprost produced a statistically greater reduction of IOP than unoprostone in Japanese patients with POAG or OH.
H.K. Mishima, MD, Department of Ophthalmology and Visual Science, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. hkmishi;cahiroshima-u.ac.jp
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
